Eli Lilly reaches cooperation with RNA editing to treat liver and central nervous system diseases
Eli Lilly and ProQR reach $1.3 billion collaboration on RNA editing therapy
Novo Nordisk, Eli Lilly, Gan Li and other ten pharmaceutical companies will be fighting soon!
Eli Lilly's RET inhibitor Selpercatinib capsule plans to be included in priority review
Eli Lilly invests over 1.6 billion U.S. dollars in LYTAC protein degradation technology
Eli Lilly Baritinib receives FDA emergency authorization for single-drug treatment of COVID-19 hospitalized patients
Eli Lilly's Lyumjev U.S. label expands continuous subcutaneous insulin infusion drug delivery via insulin pump
Eli Lilly's breast cancer drug Verzenios is recommended by NICE
More than half of the patients' skin symptoms improved by more than 75%. Eli Lilly's eczema antibody therapy reached the phase 3 clinical endpoint
Alzheimer's disease antibody therapy application is submitted soon, Eli Lilly updates company structure
Eli Lilly and Company announces the launch of new indications for "ramoxiuximab"
Lancet: In the treatment of type 2 diabetes, Eli Lilly's tirzepatide clinically defeated the "net celebrity hypoglycemic drug" semaglutide!
PD-1/TIGIT bispecific antibody enters clinical joint development by Cinda and Eli Lilly
Eli Lilly Olumiant's application for new indications is delayed in the U.S. review
Eli Lilly's IL-17A inhibitor Taltz is approved by NICE in the UK for the treatment of axial spondyloarthritis
New progress in oral SERD: Sanofi and Eli Lilly announce test results
Eli Lilly and Novo Nordisk provide the latest research positive data on type 2 diabetes
Express US$700 million to help AI-driven drug development for "gradual freezing", Eli Lilly and Verge reached a partnership
Eli Lilly's Alzheimer's disease treatment donanemab receives breakthrough therapy designation
Express is automatically activated according to blood sugar levels, and Eli Lilly gets "smart" insulin therapy